2020
Molecular and clinicopathologic characterization of intravenous leiomyomatosis
Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overComparative Genomic HybridizationCyclin D1Cyclin-Dependent Kinase Inhibitor p16FemaleHumansLeiomyomatosisMiddle AgedPhosphorylationUterine NeoplasmsUterusConceptsIntravenous leiomyomatosisAggressive clinical behaviorClinical behaviorArray comparative genomic hybridizationCyclin D1Uterine smooth muscle tumorsSmooth muscle tumorsSmooth muscle proliferationRecurrent chromosome alterationsCommon genetic alterationsFH immunohistochemistryClinicopathologic characterizationImmunohistochemical findingsMesenchymal tumorsMuscle tumorsBenign appearanceMuscle proliferationUterine leiomyomaGroup 1Group 3Nonneoplastic tissuesIndex scoreVascular morphologyProtein expressionComparative genomic hybridization
2010
Inverse p16 and p63 Expression in Small Cell Carcinoma and High-Grade Urothelial Cell Carcinoma of the Urinary Bladder
Buza N, Cohen PJ, Pei Hui, Parkash V. Inverse p16 and p63 Expression in Small Cell Carcinoma and High-Grade Urothelial Cell Carcinoma of the Urinary Bladder. International Journal Of Surgical Pathology 2010, 18: 94-102. PMID: 20164052, DOI: 10.1177/1066896909359914.Peer-Reviewed Original Research